Abcam, ab258757, Human VCPIP1 (VCIP 135) knockout HeLa cell lysate

Size: 1Kit
VCPIP1 KO cell lysate available now. KO validated by. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon 1 and Insertion of the selection cassette in exon 1.
Key facts
Cell type:HeLa,
Species or organism:Human,
Tissue:Cervix,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon 1 and Insertion of the selection cassette in exon 1.,
Disease:Adenocarcinoma

Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our
limited use license
patent pages

Properties and Storage Information:
Gene name-VCPIP1, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
VCIP135 also known as VCP-interacting protein p135 plays an important role in the process of membrane fusion. This protein has a mass of approximately 135 kDa and is found mainly in the cytosol and nucleus of cells. It directly interacts with valosin-containing protein (VCP) which is important for various cellular functions. The expression of VCIP135 has been noted across multiple tissues highlighting its diverse involvement in cellular activities.
Biological function summary
VCIP135 facilitates endoplasmic reticulum and Golgi membrane fusion by interacting within the VCP complex. In this mechanism it regulates the dynamics of vesicle trafficking and processing influencing the maintenance of cellular homeostasis. By ensuring proper fusion and reassembly of vesicular membranes VCIP135 impacts how well a cell manages its transport and secretory pathways. Its function in coordinating membrane systems confirms its integral role in cell integrity.
Pathways
VCIP135 significantly contributes to the ER-associated degradation (ERAD) and protein ubiquitination pathways. During these processes VCIP135 collaborates closely with proteins such as ubiquitin and VCP to direct the proper destruction of misfolded proteins. This cooperation ensures that the cell adequately manages protein quality control preventing the build-up of harmful nonfunctional proteins. These processes are essential in safeguarding cellular health and consistent workflow of molecular machinery.
Improper function of VCIP135 links to neurodegenerative disorders such as Parkinson's disease and inclusion body myopathy. These conditions often involve protein aggregation due to deficient ubiquitin-proteasome system activity a pathway in which VCIP135 retains functionality through its interaction with VCP. Aberrations in this pathway lead to toxic protein build-up which in turn impacts neuron and muscle cell survival. Understanding VCIP135's role in these diseases aids in developing therapeutic strategies toward modulation of its activity.